- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04685044
Testing a 32-channel Transmit/Receive MRI Head Array
March 17, 2023 updated by: Lawson Health Research Institute
Testing the IH 1Tx32Rx Head Array, a 32-channel Transmit/Receive Radiofrequency (RF) Array
Magnetic resonance imaging (MRI) is a diagnostic tool in medicine that generates high quality images of the human body without the use of x-rays.
Volunteers will be asked to participate in a study to evaluate improved MRI hardware that can be used to enhance the ability of MRI as a diagnostic tool.
Specifically, this hardware is designed to acquire high quality images of the brain.
This MRI hardware will eventually be integrated into a positron emission tomography (PET) system, which will be able to detect trace amounts of brain disease and/or brain function simultaneously with MRI.
The combined system is known as a PET/MRI.
For the purposes of this test, the investigators are just evaluating the MRI hardware, which will be installed in a plastic mockup of the PET system.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 4V2
- St. Joseph's Health Care, London
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18-75 years old
- Must be able to give consent
- Must complete the MRI screening questionnaire
Exclusion Criteria:
- Contraindications to MRI procedure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Healthy Volunteers
BrainPET insert
|
BrainPET insert
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quantitative equivalence or improvement of MRI image quality relative to the current mMR Array
Time Frame: 1 year
|
(i) Quantitative Analysis: MRI data will be acquired and analyzed to assess image homogeneity, signal-to-noise ratio (SNR), and contrast-to-noise ratio (CNR) for identical MRI pulse sequences acquired with each RF coil.
In addition, we will assess quality parameters such as the g-factor and noise correlation coefficients of each coil for different acceleration factors in both phantoms and volunteers.
Simple statistical tests like the paired Student's t-test will be applied to any metrics
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Qualitative equivalence or improvement of MRI image quality relative to the current mMR
Time Frame: 1 year
|
(i) Qualitative Analysis: Trained readers will search for visually discernible artifacts, compare image quality (subjective measures of contrast, noise and resolution) and check whether the Tx/Rx Array will provide similar clinical diagnostic accuracy (sensitivity and specificity) to the mMR Array.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2020
Primary Completion (Anticipated)
December 31, 2023
Study Completion (Anticipated)
December 31, 2023
Study Registration Dates
First Submitted
November 9, 2020
First Submitted That Met QC Criteria
December 22, 2020
First Posted (Actual)
December 28, 2020
Study Record Updates
Last Update Posted (Actual)
March 20, 2023
Last Update Submitted That Met QC Criteria
March 17, 2023
Last Verified
August 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- 114960
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Magnetic Resonance Imaging
-
BayerCompletedMagnetic Resonance Imaging | Magnetic Resonance AngiographyPoland, China, France, Germany, Hungary, Korea, Republic of, South Africa, Spain, Thailand, Taiwan, Czech Republic, Hong Kong, Italy, Kazakhstan, Russian Federation, Bosnia and Herzegovina, Greece, Canada, Vietnam, Kyrgyzstan
-
Centre Hospitalier Régional Metz-ThionvilleUniversity of LorraineRecruitingMagnetic Resonance ImagingFrance
-
Centre Hospitalier Universitaire, AmiensCompletedMagnetic Resonance ImagingFrance
-
Jessa HospitalCompletedMagnetic Resonance ImagingBelgium
-
BayerCompletedMagnetic Resonance ImagingUnited States, Korea, Republic of, France, Germany, Italy, Switzerland, United Kingdom
-
Boston Scientific CorporationCompletedMagnetic Resonance ImagingSpain, Hong Kong, Germany, Israel, United Kingdom, Italy, United States, Malaysia, Belgium
-
MegaPro Biomedical Co. Ltd.CompletedMagnetic Resonance ImagingTaiwan
-
BayerCompletedMagnetic Resonance ImagingJapan
-
BayerCompletedMagnetic Resonance ImagingPhilippines
-
BayerCompletedMagnetic Resonance Imaging | Myocardial Perfusion ImagingSwitzerland, Germany, Austria, Poland